Concerning these existing molecules that target the TCA cycle, the literature does not indicate any action on the CCT complex; nevertheless, their potential activity on the complex cannot be disregarded, and the CCT/PHD or CCT/VHL complex might be viewed as a biomarker for novel molecules by reprogramming metabolism in GBM. The gene discussed is FLVCR2; the disease is glioblastoma.